EST. 2021

TechImmune LLC was founded in 2021 around the T cell antigen platform technology exclusively licensed from the University of California with the mission to develop novel strategies against Coronaviruses to protect the public and economic health of individuals and societies globally. Discoveries made by TechImmune during the past 5 years have provided a strong rationale for the development of an effective immunotherapeutic intervention to treat the debilitating effects of Long COVID. The company is led by a seasoned leadership team with a strong track record of success in all aspects of drug discovery, development and commercialization. Collectively, the officers and board members have launched dozens of successful companies and multiple healthcare products. To date, TechImmune has been funded through private equity, NIH grants and donations through our partnership with the University of California, Irvine.

OUR LEADERSHIP TEAM

James F. Young, PhD

Dr. James F. Young PhD
Executive Chairman

With over 40 years’ experience in vaccine science, immunology, and pharmaceutical development. Dr. Young served as the Novavax Board of Directors Chairman from 2011- 3/25. Prior to Novavax, he served as President of Research and Development at MedImmune. He played a key role in the Operation Warp Speed effort while at Novavax.

Dr. Young received his PhD from Baylor College of Medicine and a postdoctoral fellowship at Mt. Sinai School of Medicine in New York.

Gavin Herbert

VICE CHAIRMAN

Mr. Herbert has spent over 50 years in the pharmaceutical industry. He is the co-founder of Allergan Inc., CEO and Chairman of the Board for 30 years. Mr. Herbert served as Executive Vice President of SmithKline Beckman. He received his B.S. in Business, from the University of Southern California.

Jeffrey Ulmer, PhD

CEO and Board Member

Dr. Ulmer has >30 years of experience in Vaccines R&D and most recently served as the Global Head of External Research at Novartis and the Head of Preclinical R&D US at GSK Vaccines. Specialties: Biochemistry, Immunology and Cell Biology. Dr. Ulmer received his PhD from McGill University and post-doctoral fellowship at Yale University School of Medicine.

Lbachir BenMohamed, PhD

LBachir BenMohamed
Vice President and Board Member

Lbachir BenMohamed, Ph.D.—TechImmune’s vice president, board member, is the key developer and co-inventor of TechImmune’s new, promising T-cell-based immunotherapies for treating chronic Long COVID. A graduate of the Pasteur Institute in Paris, France, he has been a Professor of Immunology at UC Irvine for the last 23 years and the Director of the Laboratory of Cellular and Molecular Immunology at the Gavin S. Herbert Eye Institute. Dr. BenMohamed has over 30 years of experience in vaccines and immunotherapies, a successful record of NIH funding, and a national and international reputation in pre-clinical and clinical development of vaccines and immunotherapies with more than 125 peer-reviewed papers.

Dan Gil, PhD

Daniel Gil Headshot
COO and Board Member

Dr. Gil has had a 30+year career in Pharmaceutical R&D as VP of Research at Allergan. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from University of Pennsylvania.

Dr. Trevor Jones CBE, PhD, DsC

Board Member

Former Head of Research for Burroughs Welcome, UK for over 20 years. Served as Head of British Pharmaceutical Association. He has been an advisor to the UK Government and G7 pandemic preparedness “100” days initiatives
to develop diagnostics, vaccines, and therapeutics for global use.

James H. Cavanaugh, PhD

James Cavanaugh PhD
Board Member

Dr. Cavanaugh is the former Managing Director and Senior Advisor to HealthCare Venture LLC, a private equity and venture capital firm specializing in early stage biotechnology investments. He was previously President of SmithKline & French. He also served as President of Allergan International. Dr. Cavanaugh received his B.S. from Farleigh Dickinson University, M.A. and his Ph.D. from University of Iowa.

Gregory M. Glenn, M.D.

Gregory M. Glenn, M.D.
Scientific Advisor

The former Novavax R&D President has over 30 years of experience in vaccine development, including a fellowship at WRAIR and founding IOMAI for skin-based vaccine delivery, later acquired by Intercell (now Valneva). Joining Novavax in 2010, he specialized in adjuvant and delivery systems for RSV, Influenza, and COVID-19, co-authoring over 140 publications and contributing to the licensure of MatrixM/R21 (Malaria) and Nuvaxovid (COVID-19) vaccines.

Robert Redfield, M.D

Robert Redfield, M.D.
Scientific Advisor

Dr. Redfield is the former Director of the Centers for Disease Control and Prevention and a distinguished public health leader with decades of experience in medicine and research. He played a key role as a contributor to Operation Warp Speed, helping accelerate the development of life-saving vaccines during the COVID-19 pandemic. Today, he continues to advance the field through his active involvement in Long COVID clinical research.

Feb 2023

Current Situation and Future Needs

Since early 2020, a deadly pandemic caused by a new Coronavirus (SARS-CoV-2) has threatened public health, world economies, and quality of life on a global scale. As of March 2024, the COVID-19 outbreak has resulted in 775 million confirmed cases and >7 million deaths worldwide ().

Unlike the previous CoV outbreaks, which were successfully managed using public health measures, containment of SARS-CoV-2 will require a concerted effort involving vaccines and therapeutics, along with public health measures. While the successes with first generation of CoV vaccines have been remarkable, it is becoming clear that a better and long-term solution to end the current pandemic and prevent future outbreaks is desperately needed.

During the COVID-19 outbreak, mutations and deletions in the Spike protein gene have produced a succession of fast spreading and pathogenic SARS-CoV-2 variants of concern (VOCs) with the potential to escape vaccine-induced immunity. Despite the deployment of >13 billion doses of CoV vaccine worldwide,  COVID-19 still accounts for 3 times as many deaths as influenza. These stark numbers emphasize the need for a superior, next-generation vaccine that induces broad-based, cross-reactive, and long-lasting immunity.

Recently, the Food & Drug Administration (FDA) announced a recommendation that  vaccines should be given on an annual basis, confirming the belief of the scientific community that COVID-19 with will be with us for a long time.

The Need

Long COVID (also known as PASC or post-COVID syndrome) is a complex condition that can affect nearly every major organ system, with symptoms ranging from brain fog, fatigue, and neuropathic pain to anxiety, depression, and sleep disturbances. For millions, these symptoms persist for months or even years, disrupting daily life and quality of life.

Globally, more than 400 million people are estimated to be affected, including 5-7% of the U.S. population. Despite over 150 clinical trials, no effective therapies have yet been identified. The human toll, combined with an economic impact measured in the trillions of dollars, underscores the urgent need for breakthrough treatments that address the root cause of Long COVID.

The Opportunity

Long COVID is a growing global health challenge, arising in ~6% of the 300 million new COVID-19 cases each year. In the U.S., 10–20 million people are currently affected, with 3–3.5 million projected to seek treatment for moderate to severe disease. The endemic nature of COVID-19 will generate a sustained and expanding patient population with a continued need for effective therapies. TechImmune’s approach is uniquely designed to target the root cause of disease by restoring functional anti-viral immunity, with the potential to deliver the first approved therapeutic intervention for Long COVID.

GRANTS and CONTRACTS

TechImmune, LLC has been awarded a business (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases (NIH) to develop a Universal Vaccine Against Multiple Coronavirus Variants of Concern.

Additional grants are pending.

TechImmune has an exclusive license agreement that covers 6 patent applications. Future government grants are pending in the current year.

FUNDING STRATEGY

TechImmune continues to raise additional funding in the 1st half of 2024.

Email Us

TECHIMMUNE
INVESTOR INFORMATION

Chris Graham

INVESTOR RELATIONS
Christine Dwight

contact@techimmune.com

+1 (949) 691-4350
5270 California Avenue, Suite 300
Irvine, CA. 92617

Join Our Mission!